logo
Plus   Neg
Share
Email

AstraZeneca Says Imfinzi Approved In China For Stage III NSCLC - Quick Facts

AstraZeneca (AZN,AZN.L) announced that Imfinzi has been approved in China for the treatment of unresectable, Stage III non-small cell lung cancer based on the Phase III PACIFIC trial.

The approval of Imfinzi is based on results from the primary analysis of progression-free survival and supported by overall survival from the Phase III PACIFIC trial. Results showed a statistically significant and clinically meaningful OS and PFS benefit for treatment with Imfinzi vs. placebo after concurrent chemotherapy and radiation therapy.

Imfinzi reduced the risk of death by 32% and prolonged the time patients lived without disease progression or death by more than 11 months.

Dave Fredrickson, Executive Vice President, Oncology Business Unit said, "This approval illustrates our long-standing commitment to improving health outcomes in China, where more than one-third of the world's lung cancer diagnoses and deaths occur. As the global standard of care in this curative-intent setting, Imfinzi is an important new option for patients in China."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Electric Co. filed a lawsuit against Siemens Energy AG, accusing the German power distribution company of stealing trade secrets for gas turbines. Siemens Energy allegedly used the information to get at least nine contracts to supply gas turbines to public utilities, and also covered up improper business gains. Following a court ruling, the U.S. Food and Drug Administration postponed the effective date for tobacco manufacturing companies to display new health warnings on cigarette packets and in advertisements, by additional 90 days. The warnings with color images is to promote greater public understanding of the negative health consequences of smoking. JPMorgan Chase & Co (JPM) reported strong results in the fourth quarter of 2020, with net profit up 42% largely driven by credit reserve releases of $2.9 billion. The Group said it ended the year with a CET1 ratio of 13.1% and capital above $200 billion, providing with meaningful capacity to further...
Follow RTT